Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 37Rituximab 31fludarabine phosphate 26Filgrastim 20ibrutinib 19Bortezomib 19fludarabine 17Peripheral Blood Stem Cell Transplantation 15Lenalidomide 15Bendamustine Hydrochloride 14Etoposide 12Cytarabine 9aldesleukin 7Vorinostat 7Tacrolimus 7Radiotherapy 7Prednisone 7Paclitaxel 7Melphalan 7Cyclosporine 7Biopsy 7venetoclax 6tanespimycin 6sargramostim 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carmustine 6Vincristine 5Specimen Handling 5Polymerase Chain Reaction 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Mantle-Cell × Appointments and Schedules × Clear all
NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Juno Therapeutics, a Subsidiary of Celgene

Phase 1 Completed
387 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡